Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2019 | The success story of bispecific and trispecific antibodies

Hermann Einsele • 25 Mar 2019
EBMT 2019
General Antibodies

Beyond CAR T-cell therapy, bispecific and trispecific antibodies prove to be promising, which Hermann Einsele, MD, FRCP University Hospital Würzburg, Würzburg, Germany, discusses at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.

More from Hermann Einsele

2:44
Moving CAR-T into earlier lines of therapy in multiple myeloma
Hermann Einsele • 17 Feb 2024
0:45
CAR T-cell therapy in lenalidomide-refractory multiple myeloma
Hermann Einsele • 17 Feb 2024
1:19
Sequencing bispecific antibodies and CAR-T therapy & the evolving role of bispecifics in myeloma
Hermann Einsele • 26 Jun 2023
8:16
Results from CARTITUDE-4: cilta-cel for lenalidomide-refractory multiple myeloma
Hermann Einsele • 26 Jun 2023

Related Videos

3:11
Exercise as an underutilized tool in cancer care
Rebecca Robinson • 23 Apr 2024
2:30
The impact of conflict on access to cancer therapies
Richard Sullivan • 29 Apr 2024
2:15
Cardiac biomarkers for immune checkpoint inhibitor-related myocarditis in cancer patients
Arjun Ghosh • 25 Apr 2024
1:09
Rethinking healthcare to improve affordability, sustainability, and patient outcomes
Richard Sullivan • 29 Apr 2024
The content of VJHemOnc is intended for healthcare professionals